Get the Stockscreener App
1.17
6.40%
-0.08
After Hours:
1.17
Hookipa Pharma Inc stock is traded at $1.17, with a volume of 101.56K.
It is down -6.40% in the last 24 hours and down -38.42% over the past month.
HOOKIPA Pharma Inc is a clinical-stage biopharmaceutical company developing a class of immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform that is designed to reprogram the body's immune system. Its oncology portfolio targets oncoviral cancer antigens and next-generation antigens and includes two primary programs in development: eseba-vec (formerly HB-200) and HB-700. Eseba-vec is in clinical development for the treatment of Human Papillomavirus 16-positive (HPV16+) head and neck cancers. It also develops infectious disease therapies in partnership with other companies. Its Hepatitis B (HBV) program, HB-400, and Human Immunodeficiency Virus (HIV) program, HB-500, are being developed in partnership with Gilead.
See More
Previous Close:
$1.25
Open:
$1.26
24h Volume:
101.56K
Relative Volume:
0.85
Market Cap:
$14.11M
Revenue:
$52.16M
Net Income/Loss:
$-48.60M
P/E Ratio:
-0.2708
EPS:
-4.32
Net Cash Flow:
$-77.48M
1W Performance:
-10.00%
1M Performance:
-38.42%
6M Performance:
-76.55%
1Y Performance:
-84.22%
1-Day Range:
$1.16
$1.35
1-Week Range:
$1.11
$1.35
52-Week Range:
$1.11
$10.50
Hookipa Pharma Inc Stock (HOOK) Company Profile
Name
Hookipa Pharma Inc
Sector
Industry
Phone
0114318906360
Address
350 FIFTH AVENUE, 72ND FLOOR, SUITE 7240, NEW YORK, NY
Compare HOOK with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
HOOK
Hookipa Pharma Inc
|
1.17 | 14.11M | 52.16M | -48.60M | -77.48M | -4.32 |
|
VRTX
Vertex Pharmaceuticals Inc
|
502.92 | 129.14B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
680.61 | 74.41B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
581.21 | 35.31B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
241.75 | 31.30B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
254.57 | 27.35B | 3.32B | -860.46M | -1.04B | -8.32 |
Hookipa Pharma Inc Stock (HOOK) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-20-24 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Nov-15-24 | Reiterated | RBC Capital Mkts | Outperform |
| Dec-02-22 | Downgrade | BofA Securities | Buy → Underperform |
| Nov-12-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Apr-08-21 | Initiated | Morgan Stanley | Overweight |
| Nov-03-20 | Initiated | Truist | Buy |
| Oct-26-20 | Initiated | JMP Securities | Mkt Outperform |
| Oct-19-20 | Resumed | H.C. Wainwright | Buy |
| Sep-27-19 | Initiated | H.C. Wainwright | Buy |
| May-13-19 | Initiated | BofA/Merrill | Buy |
| May-13-19 | Initiated | RBC Capital Mkts | Outperform |
View All
Hookipa Pharma Inc Stock (HOOK) Latest News
Hookipa Pharma (HOOK) Expected to Announce Earnings on Thursday - Defense World
Hookipa Pharma stock hits 52-week low at $1.34 amid sharp decline - Investing.com Australia
Hookipa Pharma stock hits 52-week low at $1.34 amid sharp decline By Investing.com - Investing.com South Africa
HOOKIPA Pharma Inc. SEC 10-K Report - TradingView
Hookipa Pharma stock hits 52-week low at $1.56 amid downturn - Investing.com India
Hookipa Pharma stock hits 52-week low at $1.56 amid downturn By Investing.com - Investing.com South Africa
Will HOOKIPA Pharma Inc. (HOOK) Report Negative Q2 Earnings? What You Should Know - MSN
BRIEF—Proposed combination of Poolbeg with HOOKIPA called off - The Pharma Letter
HOOKIPA Pharma ends talks to acquire Poolbeg Pharma By Investing.com - Investing.com Australia
Poolbeg slumps as Hookipa merger is called off - pharmaphorum
Hookipa Pharma (NASDAQ:HOOK) Shares Down 4.8% – Time to Sell? - Defense World
Poolbeg Pharma PLC (AIM:POLB) Termination of proposed combination with HOOKIPA - Share Talk
Poolbeg merger off after HOOKIPA ends discussions - Proactive Investors UK
Poolbeg Pharma Says Hookipa Terminated Discussions On Proposed Merger - TradingView
HOOKIPA Pharma Inc. (“HOOKIPA”) Statement regarding potential combination for Poolbeg Pharma plc (“Poolbeg”) - GlobeNewswire
HOOKIPA Pharma ends talks to acquire Poolbeg Pharma - Investing.com India
Failed Merger: Why HOOKIPA Pharma Walked Away from Poolbeg Deal - StockTitan
Hookipa Pharma stock hits 52-week low at $1.71 amid downturn - MSN
Hookipa Pharma announces enrollment completion of Phase 1b HB-500 trial - Yahoo Finance
Hookipa Pharma Files Petition to Validate Stockholder Actions at Annual Meetings - Defense World
HOOKIPA completes enrollment for HIV vaccine trial By Investing.com - Investing.com Nigeria
HOOKIPA Pharma seeks court validation for stockholder actions By Investing.com - Investing.com Australia
HOOKIPA completes enrollment for HIV vaccine trial - Investing.com India
HOOKIPA Pharma Announces Enrollment Completion of Phase 1b - GlobeNewswire
Game-Changing HIV Vaccine Trial Fully Enrolled: HOOKIPA's Path to Potential Cure - StockTitan
HOOKIPA Pharma Announces Enrollment Completion of Phase 1b Clinical Trial Evaluating HB-500 for the Treatment… - Informazione.it
Poolbeg Agrees to Bid Deadline Extension for Possible Hookipa Pharma Deal - MarketWatch
Poolbeg and HOOKIPA given more time to agree merger deal - Proactive Investors UK
Poolbeg Pharma PLC (AIM:POLB) Offer Update – Extension to PUSU Deadline - Share Talk
Poolbeg Pharma granted extension to PUSU Deadline - DirectorsTalk Interviews
Poolbeg Pharma and HOOKIPA Extend Merger Deadline Amid Positive Discussions - TipRanks
HOOKIPA Pharma seeks court validation for stockholder actions - MSN
Hookipa Pharma Seeks Validation for Stockholder Meetings - TipRanks
HOOK (HOOKIPA Pharma) Shares Outstanding (EOP) : 12.05 Mil (As of Sep. 2024) - GuruFocus.com
Hookipa Pharma stock hits 52-week low at $1.73 amid market challenges - Investing.com Nigeria
Geode Capital Management LLC Cuts Stake in Hookipa Pharma Inc (NASDAQ:HOOK) - Defense World
HC Wainwright Reiterates Neutral Rating for Hookipa Pharma (NASDAQ:HOOK) - Defense World
HOOKIPA Pharma explores acquisition of Poolbeg Pharma By Investing.com - Investing.com South Africa
HOOKIPA Pharma explores acquisition of Poolbeg Pharma - Investing.com
Hookipa Pharma Inc Stock (HOOK) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.39%
0.55%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):